Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening
  • USA - English


News provided by

ECOG-ACRIN Cancer Research Group

Jul 25, 2014, 14:40 ET

Share this article

Share toX

Share this article

Share toX

Lead investigator Ilana F. Gareen, PhD
Lead investigator Ilana F. Gareen, PhD

Philadelphia, PA (PRWEB) July 25, 2014 -- A new study of participants in the National Lung Screening Trial (NLST), the results of which are published today in Cancer, found evidence that men and women between the ages of 55 and 74 who had an abnormal finding on a lung cancer screening test did not experience more anxiety or reduced quality of life than did those who were screened and found to be cancer-free.

In advance of the screening, participants were advised that 20 to 50 percent of those screened would receive false positive results, and that the participants might require additional work-up to confirm that they were cancer free,” said Gareen.

Post this

This result came as a surprise to the researchers. “We expected that participants with an abnormal finding would be more worried and uneasy about that finding,” said lead study author Ilana F. Gareen, Ph.D., assistant professor of epidemiology research at the Brown University Center for Statistical Sciences, Providence, R.I. “Instead we found that people had anxiety levels and quality of life that were similar, whether their screening test found something suspicious or nothing at all.”

Gareen and her colleagues hypothesize that the thorough consent process used in the NLST helped mitigate potential increases in anxiety and/or declines in health-related quality of life. The consent form for the NLST was vetted by patients and clinicians and aimed to fully inform trial participants ahead of time that the screening test they were about to undergo frequently shows abnormal findings (called positive results) that may later be deemed negative/not cancer, after further testing. “In advance of the screening, participants were advised that 20 to 50 percent of those screened would receive false positive results, and that the participants might require additional work-up to confirm that they were cancer free,” said Gareen.

The study, Impact of Lung Cancer Screening Results on Participant Health-Related Quality of Life and State Anxiety in the National Lung Screening Trial, is available online at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28833/pdf. It was conducted through the American College of Radiology Imaging Network (ACRIN), now part of the ECOG-ACRIN Cancer Research Group, with funding from the National Cancer Institute (NCI).

"At the introduction of agreeing to participate in the NLST, I was fully aware of the potential ramifications of whatever potential medical results that might be given to me as an outcome of the screening, knowing full well that tests do come back with false-positives at times,” said participant Kit Spikings. “This truly did not play a factor or have any negative connotation for me to second-guess if I truly wanted to partake in the NLST. I believe I was more concerned with the final results of the NLST, and the chance to take part in a study so important and so vital to every human being who smokes."

The U.S. Preventive Services Task Force recommends low-dose CT screening every year for people between 55 and 80 years old who are at high risk for lung cancer because they are currently heavy smokers or have quit within the past 15 years. The recommendation is based, in large part, on the central finding of the NLST, published in the New England Journal of Medicine (2011), that low-dose computerized tomography (CT) is associated with a 20 percent reduction in lung cancer mortality compared to chest x-ray (CXR).

However, a major barrier to the adoption of low-dose CT screening is the concern that the high rate of false positive findings may cause undue worry, dread and fear among people. “False positive” is a term used by physicians to describe a screening test in which findings initially indicating concern for cancer are later found not to be cancer.

“These results are very gratifying, given that one of the concerns with CT screening is patient anxiety. It also reinforces that fact that communication between the health care provider and patient is critical for both informed decision-making and understanding the implications of test results,” said NLST lead investigator Denise R. Aberle, MD, professor of radiology and bioengineering vice chair, research, at the University of California, Los Angeles, as well as deputy chair of ECOG-ACRIN’s Imaging Sciences.

Gareen and co-authors mailed questionnaires to a subset of NLST participants at 16 facilities that perform lung screening. Psychological effects of screening were assessed at the Brown University’s Center for Statistical Sciences through the use of two measurement tools, one evaluating anxiety and the other assessing health related quality of life, sent in the mail one month after screening and again at six months.

About the NLST Consent Form
Currently, there is no standard consent form used in lung cancer screening. Facilities that perform lung screening may explain the procedure to patients using whatever consent form they choose. There is no standard information provided to patients regarding false positive results. The consent form used in the NLST is part of an accompanying fact sheet available online at ecog-acrin.org.

Other Findings
The study also found that there were no changes in the levels of anxiety or quality of life at one month or six months after screening for participants having an abnormal finding. “We measured at one month and six months because we expected that there would be greater anxiety and reduced quality of life initially, and that these feelings would subside over time,” said Gareen. Additionally, the results were no different whether participants received low-dose CT or CXR.

About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group is a multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group was formed in May 2012 by a merger that combined the complementary strengths of the Eastern Cooperative Oncology Group (ECOG) in cancer therapy and the American College of Radiology Imaging Network (ACRIN) in cancer imaging. ECOG and ACRIN were two highly respected NCI-sponsored cancer cooperative groups. ECOG-ACRIN comprises nearly 650 member institutions in the United States and around the world. Approximately 6,000 physicians, translational scientists and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies and Biomarker Sciences. ECOG-ACRIN is supported primarily through NCI research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. It is headquartered in Philadelphia, Pa., as is PrECOG LLC, a not-for-profit company that partners with ECOG-ACRIN and industry to develop and conduct clinical trials in all areas of oncology. For more information, visit ecog-acrin.org or call 215.789.3631.

###

Diane M Dragaud, MA, Director of Communications, ECOG-ACRIN Cancer Research Group, http://ecog-acrin.org, +1 215.789.3631, [email protected]

Modal title

The NLST found that low-dose CT scanning (pictured above) is associated with a 20 percent reduction in lung cancer mortality compared to chest x-ray.
The NLST found that low-dose CT scanning (pictured above) is associated with a 20 percent reduction in lung cancer mortality compared to chest x-ray.
"Communication between the health care provider and patient is critical for both informed decision-making and  understanding the test results," said NLST lead investigator Denise R. Aberle, MD.
"Communication between the health care provider and patient is critical for both informed decision-making and understanding the test results," said NLST lead investigator Denise R. Aberle, MD.
Full Explanation Reduces Seniors' Worries about Lung Cancer Screening Press Release PDF
View PDF
Full Explanation Reduces Seniors' Worries about Lung Cancer Screening Press Release PDF
Fact Sheet NLST Sub-Study on Participant Anxiety and Quality of Life PDF
View PDF
Fact Sheet NLST Sub-Study on Participant Anxiety and Quality of Life PDF
The NLST found that low-dose CT scanning (pictured above) is associated with a 20 percent reduction in lung cancer mortality compared to chest x-ray. "Communication between the health care provider and patient is critical for both informed decision-making and  understanding the test results," said NLST lead investigator Denise R. Aberle, MD. Full Explanation Reduces Seniors' Worries about Lung Cancer Screening Press Release PDF Fact Sheet NLST Sub-Study on Participant Anxiety and Quality of Life PDF

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.